Microbiome modification and improvement of signs and symptoms of COVID-19: Ileocolonic-release nicotinamide in a prospective, double-blind, randomized, placebo-controlled trial

Introduction Infection with SARS-CoV-2 leads to pronounced changes in the intestinal microbiome and also decay of tryptophan that are both related to disease severity. Supplementation of tryptophan metabolism using ileocolonic-release nicotinamide may stabilize the microbiome and alleviate COVID-19 symptoms.